Skip Navigation

Faculty Directory

Naor Bar-Zeev, PhD

  • Associate Professor

Departmental Affiliations

Contact Information

IMPRINT Network
AMI Collaboration
MLW Clinical Research Programme, Blantyre Malawi

View Current Courses

Education

PhD, Charles Darwin University, 2013
MBiostat, University of Melbourne, 2011
MPH, University of Melbourne, 2006
MBBS, Monash University, 1999

Overview

Dr Naor Bar-Zeev is a pediatric infectious diseases physician and statistical epidemiologist. His research interest is in understanding how to maximise the benefit of existing and future vaccines in low-resourced high mortality settings, how best to protect vulnerable groups like newborns and pregnant women and how to optimise methods to evaluate vaccine impact and effectiveness.

He is co-principal investigator on a Bill & Melinda Gates Foundation funded, WHO sponsored 7-country randomized clinical trial of azithromycin in childhood diarrhea, and co-investigator on a Gates Foundation funded randomized trial of a novel neonatal rotavirus vaccine together with colleagues at the Universities of Melbourne and Liverpool. He is undertaking typhoid cost of illness studies with colleagues at PATH, the Universities of Liverpool and of Malawi, and the TyVAC Consortium. He is a founding member of the "Immunizing Pregnant Women and Infants (IMPRINT) Network", funded by UK’s Global Challenges Research Fund (GCRF), where he leads the development of comparable methodologies for assessing efficacy in clinical trials. He is also a member of the PATH led "Advancing Maternal Immunization (AMI) Collaboration".

Prior to joining Johns Hopkins Bloomberg School of Public Health, Dr Bar-Zeev led the Vaccines Research Group at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi from 2011 to 2016, and was member of the Malawi National Immunization Technical Advisory Group. He established the Wellcome Trust funded multisite national vaccine surveillance program in Malawi (VacSurv), that included several case-control and large scale population cohort studies examining pneumococcal conjugate and rotavirus vaccine impact and effectiveness against disease endpoints and mortality as well as cost-effectiveness evaluations of vaccines in partnership with PATH. He also worked as pediatric infectious diseases specialist at Queen Elizabeth Central Hospital in Blantyre, Malawi, where he continues clinical practice on a visiting basis.

Dr Bar-Zeev is Fellow of the Royal Australasian College of Physicians, dual certified in general pediatrics and infectious diseases, Fellow of the Australasian College of Tropical Medicine, Fellow of the Royal Statistical Society (UK) and an Accredited Statistician with the Statistical Society of Australia. His PhD in epidemiology was undertaken at the Menzies School of Health Research, Charles Darwin University, in Darwin, northern Australia. Dr Bar-Zeev has 20 years’ experience in global child health across East Asia, the Pacific and Africa, and has worked with the WHO, UNICEF and Save the Children. He has received funding from Gates Foundation, PATH, CDC, NIH and industry.

Conflict of interest declaration: Dr Bar-Zeev has in the past initiated and obtained research support from Glaxo-Smith-Kline Biologicals and from Takeda Pharmaceuticals. These grants covered costs of field staff in project sites in Malawi. He has not received personal payment or any other benefit from any pharmaceutical company, and has no financial interests in the vaccine industry.

  • vaccines and immunization
  • maternal, infant and child health
  • non-specific effects
  • heterologous effects
  • epidemiology
  • clinical trials
  • low income countries
  • tropical medicine
  • Malawi
  • pneumococcal disease
  • rotavirus
  • RSV
  • health economics

Recent first author publications

  • Bar-Zeev N*, King C*, Phiri T, Beard J, Mvula H, Crampin AC, Heinsbroek E, Lewycka S, Tate JE, Parashar UD, Costello A, Mwansambo C, Heyderman RS, French N, Cunliffe NA, for the VacSurv Consortium. Impact of monovalent rotavirus vaccine on diarrhoea-associated post-neonatal infant mortality in rural communities in Malawi: a population-based birth cohort study. Lancet Glob Health 2018; 6:e1036–44 (* joint first authors)
  • Bar-Zeev N, Tate JE, Pecenka C, Chikafa J, Mvula H, Wachepa R, Mwansambo C, Mhango T, Chirwa G, Crampin AC, Parashar UD, Costello A, Heyderman RS, French N, Atherly D, Cunliffe NA; VACSURV Consortium. Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data. Clin Infect Dis. 2016 May 1;62 Suppl 2:S220-8.
  • Bar-Zeev N, Kapanda L, Tate JE, Jere KC, Iturriza-Gomara M, Nakagomi O, Mwansambo C, Costello A, Parashar UD, Heyderman RS, French N, Cunliffe NA; VacSurv Consortium. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. Lancet Infect Dis. 2015 Apr;15(4):422-8
  • Bar-Zeev N, Mtunthama N, Gordon SB, Mwafulirwa G, French N. Minimum incidence of adult invasive pneumococcal disease in Blantyre, Malawi an urban african setting: a hospital based prospective cohort study. PLoS One. 2015 Jun 3;10(6):e0128738.
  • Bar-Zeev N, Kapanda L, King C, Beard J, Phiri T, Mvula H, Crampin AC, Mwansambo C, Costello A, Parashar U, Tate JE, Verani JR, Whitney CG, Heyderman RS, Cunliffe NA, French N; VacSurv Consortium. Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi. Vaccine. 2015 May 28;33(23):2637-45.